We are live on ! Find out more
LOGC

LogicBio Therapeutics, Inc. Common Stock
LOGC

Delisted

LOGC was delisted on the 15th of November, 2022.

Back to rankings

57 hedge funds and large institutions have $37M invested in LogicBio Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 12 increasing their positions, 10 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 10

0% more funds holding

Funds holding: 57 → 57 (0)

0% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 11

49% less capital invested

Capital invested by funds: $73.2M → $37M (-$36.2M)

84% less call options, than puts

Call options by funds: $5K | Put options by funds: $32K

Holders
57
Holders Change
–
Holders Change %
0%
% of All Funds
0.88%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
12
Reduced
10
Closed
11
Calls
$5K
Puts
$32K
Net Calls
-$27K
Net Calls Change
+$16K

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$1.58M
2
Millennium Management
Millennium Management
New York
+$293K
3
SC
Samlyn Capital
New York
+$126K
4
William Blair & Company
William Blair & Company
Illinois
+$74.3K
5
Citadel Advisors
Citadel Advisors
Florida
+$62.9K

Top Sellers

Rank Fund Capital Flow
1
LPC
Lion Point Capital
New York
-$2.29M
2
E
Ergoteles
New York
-$301K
3
Renaissance Technologies
Renaissance Technologies
New York
-$216K
4
EP
Eversept Partners
New York
-$199K
5
HF
HRT Financial
New York
-$192K
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$19.6M – – –
Franklin Resources
2
Franklin Resources
California
$3.69M +$173 +51 +0%
SC
3
Samlyn Capital
New York
$3.49M +$126K +37,309 +3%
Vanguard Group
4
Vanguard Group
Pennsylvania
$1.68M -$14.2K -4,208 -0.6%
Goldman Sachs
5
Goldman Sachs
New York
$1.18M +$1.58M +466,289 +1,105%
BBA
6
Baker Bros. Advisors
New York
$1.04M – – –
PIM
7
Platinum Investment Management
Australia
$740K – – –
Fidelity Investments
8
Fidelity Investments
Massachusetts
$730K +$2.37K +700 +0.2%
EP
9
Eversept Partners
New York
$672K -$199K -58,818 -17%
HCA
10
Harbor Capital Advisors
Illinois
$653K +$956K +282,578 New
PVI
11
Pura Vida Investments
New York
$532K -$52K -15,371 -6%
BlackRock
12
BlackRock
New York
$506K +$9.72K +2,873 +1%
SCM
13
Sio Capital Management
New York
$422K – – –
Geode Capital Management
14
Geode Capital Management
Massachusetts
$319K – – –
Millennium Management
15
Millennium Management
New York
$312K +$293K +86,468 +178%
BCM
16
Bridgeway Capital Management
Texas
$284K -$181K -53,600 -30%
Verition Fund Management
17
Verition Fund Management
Connecticut
$262K – – –
FT
18
Fiduciary Trust
Massachusetts
$88K – – –
State Street
19
State Street
Massachusetts
$78K – – –
Northern Trust
20
Northern Trust
Illinois
$68K – – –
Susquehanna International Group
21
Susquehanna International Group
Pennsylvania
$58K -$71.9K -21,261 -46%
Dimensional Fund Advisors
22
Dimensional Fund Advisors
Texas
$56K +$11.1K +3,287 +16%
William Blair & Company
23
William Blair & Company
Illinois
$51K +$74.3K +21,950 New
TYCC
24
Texas Yale Capital Corp
Florida
$46K – – –
Citadel Advisors
25
Citadel Advisors
Florida
$43K +$62.9K +18,600 New
1
2 3

LOGC Hedge Fund Activity: Q4 2021 in Review

57 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in LogicBio Therapeutics, Inc. Common Stock (LOGC) for Q4 2021, worth a combined $37M — down 49% from $73.2M a quarter earlier.

Fund positioning in LOGC was balanced in Q4 2021: 11 funds opened new positions, 11 closed out, 12 added to existing stakes and 10 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $1.58M. The largest seller was Lion Point Capital, exiting entirely with an estimated $2.29M sold.

  • 57 institutional investors held LogicBio Therapeutics, Inc. Common Stock (LOGC) as of Q4 2021, unchanged from Q3 2021.
  • Funds reported $37M of LogicBio Therapeutics, Inc. Common Stock stock for Q4 2021, down 49% quarter-over-quarter.
  • 11 funds opened new LogicBio Therapeutics, Inc. Common Stock positions in Q4 2021 and 11 closed out, a net change of 0 holders.
  • The largest LogicBio Therapeutics, Inc. Common Stock buyer in Q4 2021 was Goldman Sachs, an estimated $1.58M added.
  • The largest LogicBio Therapeutics, Inc. Common Stock seller in Q4 2021 was Lion Point Capital, an estimated $2.29M sold.

Based on aggregated 13F filings for Q4 2021.